Efficacy of AHCC in Breast Cancer Patients undergoing Anthracycline or Taxan-based Anticancer Drug

Phase 2

Recruiting

• Conditions: Breast Neoplasms; Breast cancer, breast neoplasms; D001943

• Registration Number: JPRN-jRCTs031180324
• Lead Sponsor: Hamaguchi Reo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-18
• Last Update Posted: 2023-10-17

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Agree to undergo adjuvant chemotherapy and plan to receive Doxorubicin/Cyclophosphamide (AC), Epirubicin/Cyclophosphamide (EC), 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC), Paclitaxel (PTX), nab-Paclitaxel (nab-PTX), Docetaxel (DTX), or Docetaxel/Cyclophosphamide (TC) therapy

Exclusion Criteria

Currently taking dietary supplements derived from basidiomycetes (such as agaricus or health food derived from a mushroom) (allowed if discontinued for more than 7 days before the start of the study)
Currently taking dietary supplements except for multivitamins (allowed if discontinued for more than 7 days before the start of the study)
Allergy for a health food derived from a mushroom or basidiomycetes

Study & Design

• Study Type: Interventional
• Study Design: Not specified